Anaptysbio vs Ligand Pharmaceuticals
Anaptysbio and Ligand Pharmaceuticals are similar in size: $235m and $268m of revenue in their latest fiscal years. Anaptysbio grew faster (157.0% against 60.4%). Ligand Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 46.4% against -5.6%.
| Latest fiscal year | AnaptysbioANAB, 2025 | Ligand PharmaceuticalsLGND, 2025 |
|---|---|---|
| Revenue | $235m | $268m |
| Revenue growth | 157.0% | 60.4% |
| Net income | −$13.2m | $124m |
| Operating margin | 96.7% | — |
| Net margin | -5.6% | 46.4% |
| Return on equity | -24.5% | 13.5% |
| Free cash flow | $19.6m | $48.9m |
| Cash | $138m | $175m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $68.6m | $15.0m |
| Employees | 104 | 47 |
| Market value | $1.42bn | $6.26bn |
| Price vs our value range | — | Above our value range |
| Moat score | 13 (Weak) | 32 (Weak) |
| Insider trades, 12 months | 0 buys, 42 sales | 0 buys, 131 sales |